, Volume 212, Issue 4, pp 585–595

A role for delta opioid receptors in the central nucleus of the amygdala in anxiety-like behaviors

  • Jovita F. Randall-Thompson
  • Karen A. Pescatore
  • Ellen M. Unterwald
original investigation



Compounds acting on delta opioid receptors (DOR) modulate anxiety-like behaviors, yet the site of action underlying this effect is unknown. DOR mRNA and protein are expressed in the central nucleus of the amygdala, a region that plays an important role in processing fear, stress, and anxiety. We hypothesized that this brain region may contribute to the modulation of anxiety by DOR drugs.


The present study investigated the role of DOR in the central amygdala in anxiety-like behaviors.


The selective DOR agonist [D-Pen 2,5]-enkephalin (DPDPE) or antagonist naltrindole was bilaterally microinjected into the central nucleus of the amygdala of adult male Sprague Dawley rats and anxiety-like behaviors were assessed using the elevated plus maze. The effects of DOR agonists on heightened anxiety produced by stress were also investigated.


Rats injected with DPDPE into the central nucleus of the amygdala demonstrated less anxiety-like behavior, as evidenced by significantly greater number of open-arm entries and time spent in the open arms than controls. Naltrindole administered alone did not affect the duration or number of entries onto the open arms; however, naltrindole pre-treatment blocked the anxiolytic effects produced by DPDPE. Systemic administration of the selective DOR agonist, SNC80, or microinjection of DPDPE into the central amygdala prior to a swim stress blocked the anxiogenic effect produced by the swim stress.


These findings provide direct evidence that activation of DOR in the central amygdala reduces anxiety-like behavior and suggest that DOR in this area are important for regulating anxious states.


Delta opioid receptor Central nucleus of the amygdala Anxiety Elevated plus maze Swim stress DPDPE Naltrindole SNC80 


  1. Bilsky EJ, Calderon SN, Wang T, Bernstein RN, Davis P, Hruby VJ, McNutt RW, Rothman RB, Rice KC, Porreca F (1995) SNC 80, a selective, nonpeptidic and systemically active opioid delta agonist. J Pharmacol Exp Ther 273:359–366PubMedGoogle Scholar
  2. Bishop SJ (2007) Neurocognitive mechanisms of anxiety: an integrative account. Trends Cogn Sci 11:307–316CrossRefPubMedGoogle Scholar
  3. Brown PL, Hurley C, Repucci N, Drugan RC (2001) Behavioral analysis of stress controllability effects in a new swim stress paradigm. Pharmacol Biochem Behav 68:263–272CrossRefPubMedGoogle Scholar
  4. Chaki S, Nakazato A, Kennis L, Nakamura M, Mackie C, Sugiura M, Vinken P, Ashton D, Langlois X, Steckler T (2004) Anxiolytic- and antidepressant-like profile of a new CRF1 receptor antagonist, R278995/CRA0450. Eur J Pharmacol 485:145–158CrossRefPubMedGoogle Scholar
  5. Chiba T, Murase H, et al (1996) Antinociceptive activity of deltorphin analogs in the formalin test. Life Sci 59(20):1717–1722CrossRefPubMedGoogle Scholar
  6. Chieng B, Christie MJ (2009) Chronic morphine treatment induces functional delta-opioid receptors in amygdala neurons that project to periaqueductal grey. Neuropharmacology 57:430–437CrossRefPubMedGoogle Scholar
  7. Chieng B, Christie MJ, Osborne PB (2006) Characterization of neurons in the rat central nucleus of the amygdale: cellular physiology, morphology, and opioid sensitivity. J Comp Neurol 497:910–927CrossRefPubMedGoogle Scholar
  8. Devine DP, Wise RA (1994) Self-administration of morphine, DAMGO, and DPDPE into the ventral tegmental area of rats. J Neurosci 14:1978–1984PubMedGoogle Scholar
  9. Emmerson PJ, Liu MR, Woods JH, Medzihradsky F (1994) Binding affinity and selectivity of opioids at mu, delta and kappa receptors in monkey brain membranes. J Pharmacol Exp Ther 271:1630–1637PubMedGoogle Scholar
  10. Fang L, Knapp RJ, Horvath R, Matsunaga TO, Haaseth RC, Hruby VJ, Porreca F, Yamamura HI (1994) Characterization of [3H]naltrindole binding to delta opioid receptors in mouse brain and mouse vas deferens: evidence for delta opioid receptor heterogeneity. J Pharmacol Exp Ther 268:836–846PubMedGoogle Scholar
  11. Fanselow MS, Helmstetter FJ (1988) Conditional analgesia, defensive freezing, and benzodiazepines. Behav Neurosci 102:233–243CrossRefPubMedGoogle Scholar
  12. Filliol D, Ghozland S, Chluba J, Martin M, Matthes HW, Simonin F, Befort K, Gaveriaux-Ruff C, Dierich A, LeMeur M, Valverde O, Maldonado R, Kieffer BL (2000) Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. Nat Genet 25:195–200CrossRefPubMedGoogle Scholar
  13. Gallantine EL, Meert TF (2005) A comparison of the antinociceptive and adverse effects of the mu-opioid agonist morphine and the delta-opioid agonist SNC80. Basic Clin Pharmacol Toxicol 97(1):39–51CrossRefPubMedGoogle Scholar
  14. Garakani A, Mathew SJ, Charney DS (2006) Neurobiology of anxiety disorders and implications for treatment. Mt Sinai J Med 73:941–949PubMedGoogle Scholar
  15. Hirata H, Sonoda S, Agui S, Yoshida M, Ohinata K, Yoshikawa M (2007) Rubiscolin-6, a delta opioid peptide derived from spinach Rubisco, has anxiolytic effect via activating sigma1 and dopamine D1 receptors. Peptides 28:1998–2003CrossRefPubMedGoogle Scholar
  16. Israel Y, Kandov Y, et al (2005) NPY-induced feeding: pharmacological characterization using selective opioid antagonists and antisense probes in rats. Peptides 26(7):1167–1175CrossRefPubMedGoogle Scholar
  17. Jutkiewicz EM (2006) The antidepressant -like effects of delta-opioid receptor agonists. Mol Interv 6:162–169CrossRefPubMedGoogle Scholar
  18. Kameyama T, Nagasaka M (1982) The effects of analgesics on quickly-learned conditioned suppression in mice. Neuropharmacology 21:1283–1289CrossRefPubMedGoogle Scholar
  19. Kang W, Wilson SP, Wilson MA (1999) Changes in nociceptive and anxiolytic responses following herpes virus-mediated preproenkephalin overexpression in rat amygdala are naloxone-reversible and transient. Ann N Y Acad Sci 877:751–755CrossRefPubMedGoogle Scholar
  20. Kang W, Wilson SP, et al (2000) Overexpression of proenkephalin in the amygdala potentiates the anxiolytic effects of benzodiazepines. Neuropsychopharmacology 22(1):77–88CrossRefPubMedGoogle Scholar
  21. Konig M, Zimmer AM, Steiner H, Holmes PV, Crawley JN, Brownstein MJ, Zimmer A (1996) Pain responses, anxiety and aggression in mice deficient in pre-proenkephalin. Nature 383:535–538CrossRefPubMedGoogle Scholar
  22. Korte SM, DeBoer SF (2003) A robust animal model of state anxiety: fear-potentiated behaviour in the elevated plus-maze. Eur J Pharmacol 463:163–175CrossRefPubMedGoogle Scholar
  23. Mansour A, Fox CA, Akil H, Watson SJ (1995) Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci 18:22–29CrossRefPubMedGoogle Scholar
  24. Millan MJ (2003) The neurobiology and control of anxious states. Prog Neurobiol 70:83–244CrossRefPubMedGoogle Scholar
  25. Mosberg HI, Hurst R, Hruby VJ, Gee K, Yamamura HI, Galligan JJ, Burks TF (1983) Bis-penicillamine enkephalins possess highly improved specificity toward delta opioid receptors. Proc Natl Acad Sci U S A 80:5871–5874CrossRefPubMedGoogle Scholar
  26. Narita M, Kaneko C, Miyoshi K, Nagumo Y, Kuzumaki N, Nakajima M, Nanjo K, Matsuzawa K, Yamazaki M, Suzuki T (2006a) Chronic pain induces anxiety with concomitant changes in opioidergic function in the amygdala. Neuropsychopharmacology 31:739–750CrossRefPubMedGoogle Scholar
  27. Narita M, Kuzumaki N, Kaneko C, Tamai E, Khotib J, Miyatake M, Shindo K, Nagumo Y, Tanaka S, Suzuki T (2006b) Age-related emotionality is associated with cortical delta-opioid receptor dysfunction-dependent astrogliosis. Neuroscience 137:1359–1367CrossRefPubMedGoogle Scholar
  28. Nieto MM, Guen SL, Kieffer BL, Roques BP, Noble F (2005) Physiological control of emotion-related behaviors by endogenous enkephalins involves essentially the delta opioid receptors. Neuroscience 135:305–313CrossRefPubMedGoogle Scholar
  29. Paxinos G, Watson C (2007) The rat brain in stereotaxic coordinates, 6th edn. Elsevier, ElsevierGoogle Scholar
  30. Pellow S, Chopin P, File SE, Briley M (1985) Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14:149–167CrossRefPubMedGoogle Scholar
  31. Perrine SA, Hoshaw BA, Unterwald EM (2006) Delta opioid receptor ligands modulate anxiety-like behaviors in the rat. Br J Pharmacol 147:864–872CrossRefPubMedGoogle Scholar
  32. Pollier F, Sarre S, Aguerre S, Ebinger G, Mormede P, Michotte Y, Chaouloff F (2000) Serotonin reuptake inhibition by citalopram in rat strains differing for their emotionality. Neuropsychopharmacology 22:64–76CrossRefPubMedGoogle Scholar
  33. Portoghese PS, Sultana M, Nagase H, Takemori AE (1988a) Application of the message-address concept in the design of highly potent and selective non-peptide delta opioid receptor antagonists. J Med Chem 31:281–282CrossRefPubMedGoogle Scholar
  34. Portoghese PS, Sultana M, Takemori AE (1988b) Naltrindole, a highly selective and potent non-peptide delta opioid receptor antagonist. Eur J Pharmacol 146:185–186CrossRefPubMedGoogle Scholar
  35. Primeaux SD, Wilson SP, McDonald AJ, Mascagni F, Wilson MA (2006) The role of delta opioid receptors in the anxiolytic actions of benzodiazepines. Pharmacol Biochem Behav 85:545–554CrossRefPubMedGoogle Scholar
  36. Ragnauth A, Schuller A, Morgan M, Chan J, Ogawa S, Pintar J, Bodnar RJ, Pfaff DW (2001) Female preproenkephalin-knockout mice display altered emotional responses. Proc Natl Acad Sci U S A 98:1958–1963CrossRefPubMedGoogle Scholar
  37. Ramos A, Berton O, Mormede P, Chaouloff F (1997) A multiple-test study of anxiety-related behaviours in six inbred rat strains. Behav Brain Res 85:57–69CrossRefPubMedGoogle Scholar
  38. Ramos A, Mellerin Y, Mormede P, Chaouloff F (1998) A genetic and multifactorial analysis of anxiety-related behaviours in Lewis and SHR intercrosses. Behav Brain Res 96:195–205CrossRefPubMedGoogle Scholar
  39. Ramos A, Kangerski AL, Basso PF, Da Silva Santos JE, Assreuy J, Vendruscolo LF, Takahashi RN (2002) Evaluation of Lewis and SHR rat strains as a genetic model for the study of anxiety and pain. Behav Brain Res 129:113–123CrossRefPubMedGoogle Scholar
  40. Rodgers RJ, Dalvi A (1997) Anxiety, defense and the elevated plus-maze. Neurosci Biobehav Rev 21:801–810CrossRefPubMedGoogle Scholar
  41. Rodgers RJ, Johnson NJ (1995) Factor analysis of spatiotemporal and ethological measures in the murine elevated plus-maze test of anxiety. Pharmacol Biochem Behav 52:297–303CrossRefPubMedGoogle Scholar
  42. Rogers H, Hayes AG, Birch PJ, Traynor JR, Lawrence AJ (1990) The selectivity of the opioid antagonist, naltrindole, for delta-opioid receptors. J Pharm Pharmacol 42:358–359PubMedGoogle Scholar
  43. Rosen JB (2004) The neurobiology of conditioned and unconditioned fear: a neurobehavioral system analysis of the amygdala. Behav Cogn Neurosci Rev 3:23–41CrossRefPubMedGoogle Scholar
  44. Saitoh A, Kimura Y, Suzuki T, Kawai K, Nagase H, Kamei J (2004) Potential anxiolytic and antidepressant-like activities of SNC80, a selective delta-opioid agonist, in behavioral models in rodents. J Pharmacol Sci 95:374–380CrossRefPubMedGoogle Scholar
  45. Saitoh A, Yoshikawa Y, Onodera K, Kamei J (2005) Role of delta-opioid receptor subtypes in anxiety-related behaviors in the elevated plus-maze in rats. Psychopharmacology (Berl) 182:327–334CrossRefGoogle Scholar
  46. Sharif NA, Hughes J (1989) Discrete mapping of brain Mu and delta opioid receptors using selective peptides: quantitative autoradiography, species differences and comparison with kappa receptors. Peptides 10:499–522CrossRefPubMedGoogle Scholar
  47. Wall PM, Messier C (2001) Methodological and conceptual issues in the use of the elevated plus-maze as a psychological measurement instrument of animal anxiety-like behavior. Neurosci Biobehav Rev 25:275–286CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Jovita F. Randall-Thompson
    • 1
  • Karen A. Pescatore
    • 1
  • Ellen M. Unterwald
    • 1
    • 2
  1. 1.Department of Pharmacology and the Center for Substance Abuse ResearchTemple University School of MedicinePhiladelphiaUSA
  2. 2.Biology of Addictive Diseases LaboratoryThe Rockefeller UniversityNew YorkUSA

Personalised recommendations